ADVM vs. CHRS, SGMO, BDTX, CRTX, CCCC, HLVX, VALN, ITOS, TSHA, and EXAI
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Coherus BioSciences (CHRS), Sangamo Therapeutics (SGMO), Black Diamond Therapeutics (BDTX), Cortexyme (CRTX), C4 Therapeutics (CCCC), HilleVax (HLVX), Valneva (VALN), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), and Exscientia (EXAI). These companies are all part of the "medical" sector.
Coherus BioSciences (NASDAQ:CHRS) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends.
Adverum Biotechnologies has a net margin of 0.00% compared to Adverum Biotechnologies' net margin of -19.64%. Adverum Biotechnologies' return on equity of 0.00% beat Coherus BioSciences' return on equity.
Adverum Biotechnologies has lower revenue, but higher earnings than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Coherus BioSciences received 73 more outperform votes than Adverum Biotechnologies when rated by MarketBeat users. Likewise, 65.13% of users gave Coherus BioSciences an outperform vote while only 60.87% of users gave Adverum Biotechnologies an outperform vote.
In the previous week, Adverum Biotechnologies had 3 more articles in the media than Coherus BioSciences. MarketBeat recorded 7 mentions for Adverum Biotechnologies and 4 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 1.02 beat Adverum Biotechnologies' score of 0.73 indicating that Adverum Biotechnologies is being referred to more favorably in the news media.
Coherus BioSciences has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Coherus BioSciences presently has a consensus price target of $8.83, indicating a potential upside of 385.35%. Adverum Biotechnologies has a consensus price target of $29.00, indicating a potential upside of 266.16%. Given Adverum Biotechnologies' higher probable upside, equities analysts clearly believe Coherus BioSciences is more favorable than Adverum Biotechnologies.
Summary
Coherus BioSciences beats Adverum Biotechnologies on 10 of the 18 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
